Drug Identification System

PillID

Pill Identifier Drug Encyclopedia Drug Classes Compare Interactions Blog 🌙

Uses & FDA Indications

Pregabalin carries five FDA-approved indications spanning pain, seizures, and fibromyalgia. These include: diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN — nerve pain following shingles), fibromyalgia, neuropathic pain associated with spinal cord injury, and as an adjunctive (add-on) therapy for partial-onset seizures in adults.

Off-label uses are extensive and include generalized anxiety disorder (particularly in Europe, where it is approved for GAD), restless legs syndrome, alcohol withdrawal, and social anxiety disorder. Its predictable pharmacokinetics compared to gabapentin have made it a widely prescribed drug for chronic pain syndromes across multiple specialties.

How It Works

Pregabalin binds selectively to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels. These channels are found throughout the central and peripheral nervous system. By binding this subunit, pregabalin reduces calcium influx into hyperexcited neurons, decreasing the release of excitatory neurotransmitters including glutamate, substance P, and norepinephrine. The net effect is reduced neuronal excitability in pain-signaling pathways and seizure circuits.

A key pharmacokinetic advantage over gabapentin (its structural predecessor) is linear absorption. Gabapentin is absorbed by a saturable intestinal transport system, meaning absorption efficiency decreases at higher doses and blood levels are unpredictable. Pregabalin is absorbed via a different transport mechanism that is not saturable at therapeutic doses, producing consistent, proportional increases in blood levels with dose increases — making clinical titration more predictable.

Side Effects

Common

• Dizziness — one of the most frequent adverse effects; can impair driving and operating machinery.
• Somnolence / sedation — often dose-dependent; may be useful when insomnia accompanies pain, but limits daytime function.
• Peripheral edema — swelling in the extremities, particularly the lower legs. Mechanism is not fully understood; can require dose reduction or discontinuation.
• Weight gain — can be significant with long-term use; mechanism may involve increased appetite.
• Blurred vision — typically transient; double vision (diplopia) is also reported.
• Cognitive effects — difficulty concentrating, memory problems, "brain fog"; can impair occupational function.
• Dry mouth, ataxia, tremor

Serious

• Respiratory depression — particularly dangerous in combination with opioids or alcohol; potentially fatal.
• Hypersensitivity reactions — angioedema (swelling of face, mouth, throat) has been reported; if it occurs, discontinue immediately.
• Withdrawal seizures — abrupt discontinuation after prolonged use can precipitate seizures even in non-epileptic patients.
• Suicidal ideation — class effect of antiepileptic drugs.

Drug Interactions

Drug / Class	Interaction	Clinical Significance
Opioids (oxycodone, hydrocodone, morphine, fentanyl)	Additive CNS and respiratory depression. Pregabalin-opioid co-prescription is associated with increased overdose deaths. FDA has issued specific warnings about this combination.	High — avoid combination when possible; if used together, use lowest effective doses and monitor closely
Benzodiazepines (alprazolam, diazepam, clonazepam)	Additive CNS depression including sedation and respiratory depression risk.	High — use with caution; the combination of opioid + benzodiazepine + pregabalin is particularly dangerous
Alcohol	Additive CNS depression. Alcohol worsens pregabalin-related dizziness, sedation, and cognitive impairment.	Moderate-High — advise patients to avoid or minimize alcohol consumption
Other CNS depressants (muscle relaxants, sedating antihistamines, sleep aids)	Additive sedation and CNS depression.	Moderate — assess cumulative CNS depressant burden in each patient
ACE inhibitors (lisinopril, enalapril)	Additive edema risk; case reports of angioedema when combined with pregabalin.	Low-Moderate — monitor for worsening edema or angioedema

Warnings & Contraindications

Contraindications

• Hypersensitivity to pregabalin (including angioedema)

Controlled Substance — Abuse Potential

Pregabalin is federally classified as a Schedule V controlled substance, reflecting documented misuse patterns. Euphoric effects at higher doses make it susceptible to misuse, particularly among individuals with substance use disorders. Some states have placed it under stricter state-level scheduling. Prescribers should assess abuse risk before initiating, prescribe the minimum effective quantity, and monitor for signs of misuse or diversion.

Tapering on Discontinuation

Abrupt discontinuation of pregabalin can cause withdrawal symptoms: insomnia, nausea, headache, anxiety, diarrhea, and — in some cases — seizures. This risk exists even in patients without an epilepsy diagnosis. Always taper pregabalin gradually under provider supervision; the appropriate taper rate depends on dose and duration of use.

Frequently Asked Questions

Is Lyrica a controlled substance?

Yes. Pregabalin (Lyrica) is a Schedule V controlled substance under federal law in the United States, reflecting recognized abuse potential. Schedule V is the least restrictive DEA schedule — drugs in this class have accepted medical use and a lower potential for abuse compared to Schedule IV substances, but misuse and physical dependence are documented. Some individual states have placed pregabalin under stricter scheduling than the federal designation. Outside the US, pregabalin is a controlled substance in the UK, Germany, and many other countries due to rising misuse concerns.

Is pregabalin stronger than gabapentin?

Pregabalin and gabapentin share the same mechanism of action — binding to the alpha-2-delta subunit of voltage-gated calcium channels — but pregabalin has several pharmacokinetic advantages. Pregabalin is absorbed more completely and predictably than gabapentin, whose intestinal absorption is saturable (meaning higher doses do not produce proportionally higher blood levels). Pregabalin's linear pharmacokinetics allow more predictable dose-response relationships. In clinical studies, pregabalin generally demonstrates efficacy at lower absolute doses and has been shown to work faster in some neuropathic pain conditions.

Can pregabalin be abused?

Yes, pregabalin has documented abuse potential, which is why it is federally scheduled as a controlled substance. Some users report euphoric or sedating effects, particularly at higher doses, and the drug is sometimes misused in combination with opioids to amplify their effects — a dangerous combination that significantly increases respiratory depression risk. Physical dependence develops with regular use and abrupt discontinuation can cause withdrawal symptoms including insomnia, nausea, headache, anxiety, and seizures. Pregabalin should be tapered gradually when discontinuing.

→ Anticonvulsant Side Effects Guide → Chronic Pain Medications Guide → Epilepsy Medications Guide